Noro Polymerase and Protease Inhibitors
| Program | Discovery | Preclinical | Phase 1 | Phase 2a | Phase 3 |
|---|---|---|---|---|---|
| Norovirus (Gastroenteritis) Replication and Protease Inhibitor |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2a Phase not started
|
Phase 3 Phase not started
|
We continue to identify and develop non-nucleoside polymerase inhibitors using the Company’s proprietary structure-based drug design technology platform. Cocrystal recently entered into a License Agreement with the Kansas State University Research Foundation to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat Norovirus and Coronavirus infections. Preclinical activities for our Norovirus program are currently under way. The Company expects to complete its proof-of-concept animal model study in the fourth quarter of 2020.